SALT LAKE CITY, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Event at the Westin Grand Central Hotel in New York City on October 9, 2024. The in-person event will commence at 9:00 am EDT and last approximately two hours.
Paul J. Diaz, President and CEO, and other members of the Myriad executive leadership team will discuss the company’s long-term growth strategy, operational initiatives, scientific and clinical advancements reflected in its product pipeline, and long-term financial goals.
For those interested in attending the event in person, please register here. For those unable to attend in person, a live webcast of the Investor Event presentation and Q&A will be available on Myriad’s investor relations website at investor.myriad.com. A replay will be posted on Myriad Genetics’ website after the event and will be available for at least 30 days following.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Glenn Farrell
(385) 318-3718
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$14.78 |
| Daily Change: | 0.48 3.36 |
| Daily Volume: | 914,493 |
| Market Cap: | US$1.350B |
January 07, 2025 December 10, 2024 December 09, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
